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1078–5Purpose. To evaluate superficial femoral artery (SFA) occlusive disease treatment by means of covered stents.
Study design. retrospective.
Method. From 2000 to 2005, a Hemobahn/Viabahn endoprosthesis was implanted in 102 limbs (95 patients; mean age:
72.1 years, 52e94) for intermittent claudication (group I, n¼ 50 limbs), critical (group II, n¼ 32) or acute ischemia
(group III, n¼ 20). Lesions treated were Trans-Atlantic Inter-Society Consensus (TASC) A (n¼ 9) B (n¼ 42), C
(n¼ 28) or D (n¼ 23), associated with a good (2 or 3 leg arteries, n¼ 60) or a poor (1 or 0 artery, n¼ 42) runoff.
Results. The endograft was placed successfully in all cases, but 3 early deaths (3.2%) (1 in group II and 2 in group III),
and 4 acute thromboses (4%) occurred. Primary and secondary actuarial patency rates were 97 1.7%, and 99 1% at 1
month, 74 4.8% & 84 4.1% at 1 year,and 71 9.5% & 79 8.5% at 3 years, after a mean follow-up of 30.2 months
(1e60). Long-term primary and secondary patencies were significantly different between TASC Cand TASC D lesions
(P<.004 & .001).
Conclusion. Severity of lesions, rather than preoperative symptoms or runoff, is mainly to be considered before using
Hemobahn/Viabahn endoprosthesis in severe SFA occlusive lesions.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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treatment is most appropriate for severe superficial
femoral artery (SFA) lesions.1e10 Femoropopliteal by-
pass has a patency rate at 5 years of 80% for claudicants
and 66% for critical limb ischemia (CLI) when using
the saphenous vein, but only 75% and 47%with above-
knee prosthetic grafts.9 The patency rates for endovas-
cular treatment range between 65% and 77% at one
year and 48% and 66% at 3 years, depending on patient
clinical status and whether stents are used.10 Covered
stents have been suggested to prevent or limiting
myointimal ingrowth along the treated segment.1e8
In an earlier study on 32 patients we found that treat-
ing SFA occlusive lesions (excluding TASC D lesions)
with the Viabahn gave as good results for patients
with critical or acute ischemia with bad outflow as
for claudicants with good outflow if concomitant out-
flow-improving procedures were performed.1 In theponding author. Y. S. Alimi, Service de Chirurgie Vasculaire,
sity Hospital Nord, Chemin des Bourrelly, 13915 Marseille
20, France.
address: yves.alimi@ap-hm.fr
884/000346+ 07 $34.00/0  2007 European Society for Vasculapresent study we expand the earlier report to include
a larger series of patients including TASC D lesions.Methods
Study design
All patients who underwent a transluminally placed
endovascular grafts (TPEG) during the treatment of
SFA occlusive disease in our department of vascular
surgery were included. Inclusion criteria were patients
with claudication, critical limb ischemia (CLI) or acute
limb ischemia (ALI) related to SFA stenosis or occlu-
sionwith or without inflow and outflow lesions. Exclu-
sion criteria were SFA of less than 5 mm in diameter,
isolated SFA stenoses of less than 3 cm length, exten-
sion of the lesion precluding later femoropopliteal
above-knee bypass, embolic ALI and ALI category III.
All definitions are in accordance with the standards
suggested by Rutherford.10
The actuarial life-table method was used on an
intention-to-treat basis. A two-tailed Fisher exactr Surgery. Published by Elsevier Ltd. All rights reserved.
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which groups there were significant differences. The
Kaplan-Meier method estimates were calculated for
overall patency and limb salvage rates and were
then compared with the log-rank test. Patency rates
referred to the patency of the SFA procedure.Patients
From July 2000 to December 2005, 95 patients, 66 males
and 29 women, age ranging from 52 to 94 years (mean
age: 72.1 years), underwent endovascular placement of
a Viabahn endoprosthesis in 102 limbs (7 patients
with bilateral treatment).
According to preoperative symptoms, 3 groups
were distinguished:
- group I, claudicants (n¼ 50 limbs, 49%), with 43
limbs with a mean preoperative walking distance
of 124 meters (range: 10 to 199 meters, category 3
of Rutherford), and 7 limbs with a mean preopera-
tive walking distance of 278 meters (range: 200 to
380 meters, category 2 of Rutherford). Preoperative
walking distance was systematically determined
during treadmill testing. Mean ankle-brachial pres-
sure index at rest was 0.52 (range 0.3 to 0.79).
- group II, critical ischemia (n¼ 32 limbs, 32%),
with 7 limbs (8.8%) in category 4 and 25 limbs in
category 5.
- group III, acute ischemia (n¼ 20 limbs, 19%), with
8 limbs in category I, 5 limbs in category IIa and 7
limbs in category IIb, (according to the Joint Coun-
cil Classification, 8).
Preoperative risk factors are shown in Table 1. In
the overall series, 45 patients (47%) were diabetic
and 11 patients (16%) had end-stage renal failure.
The mean preoperative creatinine level of patients
not on dialysis was 1.17 mg/dl (range: 0.64 to 2.1).
Pre-operative investigations included duplex






Diabete mellitus 19 (41)
Obesity 7 (15)
Renal insuffisiencyinsufficiency 5 (11)
Ischemic heart disease 15 (33)
COPD 9 (20)
CLI: Chronic limb ischemia; ALI: Acute limb ischemia; COPD: Chronic obsangiography (n¼ 3). Seven patients in group 3 were
taken directly to the operative room and underwent
an intra-operative angiogram. According to TASC
2007 classification,11 the SFA lesions are summarized
in Table 2, with a mean lesion length of 116 mm
(35e295) in group I, 124 mm (26e302) in group II,
and 108 mm (38e298) in group III ( p non sign.). Inflow
lesions needing endovascular (n¼ 18) or surgical
(¼ 42) concomitant treatment were found in 60 limbs
(59%) (35 in group 1, 14 in group 2 and 11 in group 3),
including 21 iliac lesions and 39 femoral bifurcation
lesions (4 femoral thrombectomies in group 3, 29
thrombo-endarterectomy of the femoral bifurcation
associated with a patch enlargement and 9 short com-
mon femoral-superficial femoral bypasses).
Considering the run-off, two or three infra-
popliteal arteries were patent in 60 limbs (59%) and
only one or none in 42 limbs (41%) (41 & 9 in group
1, 10 & 22 in group 2 and 9 & 11 in group 3). A pop-
liteal (n¼ 16) or leg artery (n¼ 9) angioplasty was
performed during the same procedure, in 6 & 4 limbs
in group I, 6 & 3 limbs in group 2 and 4 & 2 limbs in
group 3. Three additional popliteal-distal bypasses
were concomitantly performed in group 2 and one
in group 3, and 6 surgical leg arteries thrombectomies
were necessary in group 3. Finally, 15 toe (n¼ 4), trans
metatarsal (n¼ 1) or tissue necrosis (n¼ 10) resections
were performed, during the same procedure in group 2.
One fasciotomy was necessary in group 3. Outflow
was statistically worse in patients with critical and
acute ischemia ( p¼ .00001) and there was a trend
for more occlusions ( p¼ .08).
Our surgical technique has been previously de-
scribed.1 Postoperatively, from the 6th hour, nadro-
parin was given subcutaneously, 2850 or 3800 U
every 12 hours depending on the patient’s weight
(less or more than 70 Kg) until discharge. In addition,
2 antiplatelet drugs (aspirin and clopidogrel) were
given for three months, and only one of the two there-
after. In cases of associated pathology or vascular re-
construction requiring oral anticoagulation therapy,







20 (69) 16 (80) 68 (72) .4
22 (76) 10 (50) 70 (74) .02
13 (45) 9 (45) 44 (46) .96
18 (62) 8 (40) 45 (47) .16
5 (17) 1 (5) 13 (14) .35
6 (21) 0 11 (16) .09
8 (27) 9 (45) 32 (34) .45
6 (21) 4 (20) 19 (20) 1
tructive pulmonary disease.
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Table 2. Severity of superficial femoral artery lesions, according to










TASC A 6 (12) 1 (3) 2 (10) 9 (9)
TASC B 22 (44) 14 (44) 6 (30) 42 (9)
TASC C 14 (72) 8 (69) 6 (60) 28 (69)
TASC D 8 (16) 9 (28) 6 (30) 23 (22)
CLI: Chronic limb ischemia; ALI: Acute limb ischemia.
348 Y. S. Alimi et al.Follow-up was performed at 1, 6 and 12 months,
then each year. Clinical examination, color-coded
Duplex ultrasound flow scan and ABI measurement
were performed at each visit.Results
Procedures
Eighteen procedures (18%) were performed under lo-
cal anesthesia and 84 under loco-regional (n¼ 2) or
general anesthesia (n¼ 82), mainly because of com-
bined inflow (n¼ 60) and/or outflow procedure
(n¼ 32), or tissue necrosis resection (n¼ 16). Percuta-
neous access to the common femoral artery (CFA) was
obtained in 44 limbs (43%); the femoral bifurcation
was surgically approached in 58 limbs (57%) due to
inflow (femoral bifurcation or iliac) lesions (54 limbs),
or unsuccessful percutaneous access (3 limbs). Sheath
size was 8 Fr in 87 limbs and 9 Fr in 15.
Technical success was achieved in 100% of patients.
Recanalization was achieved in all occluded SFAs. In
three cases, we noted dye extravasation at the level of
the recanalization and in 3 other cases, below-knee
embolic occlusionwas treatedwith thromboaspiration.
One hundred and forty-six Viabahnwere deployed [2
in 34 limbs (33%) and 3 in 5 limbs (5%), with a mean of
1.4 stent-grafts per limb to treat a mean stented area of
14.3 cm (range 2.5e37.5); 7 mm stent-grafts were used
in 15 limbs (15%) and 6 mm in all the others (85%)].
The number of procedures performed on the outflow
was statistically higher in patients with acute and crit-
ical ischemia ( p¼ .0003). Completion angiography
showed no significant residual stenosis along the
TPEG and no distal emboli.
Postoperatively, the popliteal pulse was felt in all
limbs, and distal pulses were found in 89 limbs (87%).Early follow-up (<30 days)
Overall mean hospital stay was 8.7 days (1e33). The
comparative results of the 3 different groups areEur J Vasc Endovasc Surg Vol 35, March 2008summarized in Table 3. Three deaths (3.2%), due to
postoperative myocardial infarction, occurred at day
1 & 3, in group 3 (n¼ 2) and at day 4in group 2 (n¼ 1).
Four early Viabahn occlusion (4%) occurred in
group 1 (day 1, 18, 25 and 26) and were treated either
by thrombectomy alone (n¼ 1) or with implantation
of a new Viabahn (n¼ 1) or by a femoro-popliteal by-
pass (n¼ 2).
Four postoperative complications (4%) occurred, all
in group 2: one chest pain treated by medical means,
one retroperitoneal haematoma requiring surgical
evacuation, one groin infection treated by a surgical
procedure and one leg amputation due to a severe
and infected tissue necrosis, despite a patent Viabahn
endoprosthesis with improvement of distal flow.
At one month, overall primary and secondary pa-
tency rates were 97 1.7% & 99 1%, and leg salvage
rate was 99%.
Late follow-up
Overall mean follow-up was 30.2 months (1e60).
Twelve non-related deaths (12.6%) occurred, mainly
due to myocardial infarction (n¼ 4) or cardiac insuffi-
ciency (n¼ 2). Some 23 Viabahn occlusion (23%)
were noted, generally during the first 10 months
(n¼ 21), after treatment of TASC B (n¼ 8),TASC C
(n¼ 4) or TASC D (n¼ 11) lesions.For each group, pri-
mary and secondary patency rates, as well as survival
and limb salvage rates at 3 years are summarized in
Table 4.
Follow-up in group 1 (claudicants, 46 patients, 48 limbs):
Eleven Viabahn occlusion (22.9%) occurred, mainly
between the third and the eighth month except
one occlusion at 15 months and one at 23 months.
Occlusions were treated by thrombectomy (n¼ 5),
femoro-popliteal bypass (n¼ 3) or conservatively.
Thrombectomy demonstrated a stenoses proximal or
distal to the Viabahn implantation site in most cases,
which were treated by adding two new Viabahn
endoprosthesis.
The mean overall ABPI (ankle-brachial pressure
index) increase from 0.52 (range: 0.30 to 0.79) pre-
operatively to 0.94 (0.72 to 1.1) at the end of follow-up.
Follow-up in group 2 (CLI, 26 patients, 29 limbs):Des-
pite a patent Viabahn endoprosthesis, two thigh am-
putations were necessary at 5 and 32 months for
secondary leg infection. Seven Viabahn occlusion
(24.1%) occurred between the second and eighth post-
operative months, and were treated medically (n¼ 2),
by thrombectomy (n¼ 2) or by a femoro-popliteal by-
pass (n¼ 2). In one other limb presenting with a recur-
ring ulcers, a tight stenosis distal to a patent Viabahn
endoprosthesis was discovered and treated by angio-
plasty alone.










Mean hospital stay (days, extremes) 5.1 (1e18) 10.6 (1e27) 10.3 (1e33) 8.7 (1e33)
Deaths (%) 0 1 (3) 2 (10) 3 (3.15)
Viabahn thrombosis (%) 4 (8) 0 0 4 (3.9)
Major amputation (%) 0 1 0 1 (1)
Actuarial patency
Primary (%) 92 3.8 100 100 97 1.7 .11
Secondary (%) 96 2.7 100 100 99 1 .27
Leg salvage (%) 100 97 100 99
Survival (%) 100 97 90 97
CLI: Chronic limb ischemia; ALI: Acute limb ischemia.
349Efficacy of Viabahn in the Treatment of Severe Superficial Femoral Artery LesionsFollow-up in group 3 (ALI, 16 patients, 16 limbs): Four
Viabahn occlusion (25%) occurred between the sec-
ond and the seventh month and were treated by
a femoro-popliteal bypass (n¼ 3), or a new Viabahn
endoprosthesis. The later stent-graft occluded 8
months later.
In this group, no leg amputation were necessary.
Factors influencing patency: Log-rank testing did not
reveal any statistical difference between the 3 groups
of preoperative symptoms, in terms of primary
( p¼ 0.88) or secondary ( p¼ 0.73) patency (Fig. 1). We
comparing the quality of preoperative runoff between
limbswith 2 or 3 patent tibial arteries (n¼ 60) and limbs
with one or no patent calf arteries (n¼ 42). Primary
(72 9.8% versus 68 17.2%, p¼ .94) and secondary
patency (79 8.7% versus 76 16.6%, p¼ .98) at 3
years, were not statistically different (Fig. 2). However,
among the 27 early and late Viabahn occlusions
(26.5%), 10 (23.8%) occurred after treatment of TASCTable 4. Late results (mean follow-up: 30.2 months, 1e60)
Group I
(claudication, n¼ 50)
Deaths during follow-up (%) 3 (6)
Viabahn thrombosis (%) 11 (22)
Major amputation (%) 0
Results at 1 year
Actuarial patency
Primary (%) 73 6.6
Secondary (%) 85 5.3
Leg salvage (%) 100
Survival (%) 100
Results at 3 years
Actuarial patency
Primary (%) 67 15.7
Secondary (%) 75 14.1
Leg salvage (%) 100
Survival (%) 100
CLI: Chronic limb ischemia; ALI: Acute limb ischemia.B lesions (n¼ 42), 5 (17.9%) after treatment of TASC
C lesions (n¼ 28), 12 (52.2%) after treatment of TASC
D lesions (n¼ 23), and none after treatment of TASC
A lesions (n¼ 9). Primary ( p¼ 0.001) and secondary
( p¼ 0.013) patency at 3 years were significantly differ-
ent between treatment of TASC C (respectively,
84þ 4.5% & 87þ 3.2%) and D lesions (39 21.5%
&57 37.3%) (Table 5) (Fig. 3).Discussion
When compared with the 2000 TASC recommenda-
tions, the recent 2007 modification suggests the exten-
sion of endovascular treatment indications to more
severe SFA occlusive lesions.9,11 The results of the pres-
ent study confirm that 3-years primary and secondary
SFA patency rates after Viabahn implantation (71







4 (13) 5 (28) 12 (13)
8 (26) 4 (22) 23 (23)
3 (9.7) 0 3 (3)
74 8.6 72 14.4 74 4.8 .97
81 7.7 81 12.4 84 4.1 .92
94 100 98
91 72 90
69 27.1 71 26.9 71 9.5 .88
81 7.7 71 27.1 79 8.5 .73
86 100 98
83 72 83
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Follow-up (months)
%
Fig. 1. Actuarial primary patency (Kaplan-Meier curves) for all limbs and according to preoperative symptoms ( p¼ 0.88).
Red line: All limbs (n¼ 102), Pink line: Group I (Claudicants, n¼ 50), Black line: Group II (Critical limb ischemia, n¼ 32),
Green line: Group III (Acute limb ischemia, n¼ 20).
350 Y. S. Alimi et al.above-knee femoro-popliteal saphenous vein (respec-
tively 71 & 82%) or prosthetic (59 & 68%) bypasses,
especially for TASC C lesions.10 However, our results
for TASC D lesions (primary & secondary patency of
respectively 39þ 21.5% & 57þ 37.3%, at three years)
leads us to still recommend bypass surgery for most
patients presenting with extensive SFA lesions. In a re-
view of the literature published in 2004,4 Dorucci sum-
marised a population of 318 limbs with Viabahn
implantation for SFA occlusive disease. The series
included 150 limbs with a follow-up of at least 3 years
(average lesion length of10.1 cm, percentage of occlu-
sion treated of 84%) and reported primary and second-
ary patency rates of 64% and 80% respectively.






1 3 5 7 9 11 13 15 17
m
%
Fig. 2. Actuarial primary patency (Kaplan-Meier curves) accor
arteries (n¼ 60), Pink line: 0 or 1 leg artery (n¼ 42).
Eur J Vasc Endovasc Surg Vol 35, March 2008and secondary patency at 12 months for 50 limbs
treated percutaneously with Viabahn stentgraft
(mean SD total length of artery stented was
25.6 15 cm) (75.6% & 83.9% respectively) and 50
limbs treated with a femoral-to above-knee-popliteal
artery bypass using a PTFE or a Dacron graft
(74.2% & 83.7% respectively), in a randomized
trial.12
One main concept highlighted in the literature is
the importance of selecting patients whose arterial
anatomy is optimal for endograft therapy: Fisher
et al.5 reported a series of 78 procedures and sug-
gested that the ideal indication for Viabahn implan-
tation is long SFA occlusions with at least 1 cm of
healthy vessel proximal and distal to the lesion, no19 21 23 25 27 29 31 33 35 37
onths
ding to preoperative outflow ( p¼ 0.94). Black line: 2 or 3 leg
Table 5. Preoperative parameters influencing 3-years follow-up






Gp. 1 (claudicants, n¼ 50), 67 15.7 75 14.1
Gp. 2 (CLI, n¼ 32) 69 27.1 81 7.7
Gp. 3 (ALI, n¼ 20) 71 26.9 71 27.1
p .88 .73
Preop. SFA-pop. lesions
TASC A (n¼ 9) 100 100
TASC B (n¼ 42) 79 5.9 82 5.7
TASC C (n¼ 28) 84 4.5 87 3.2
TASC D (n¼ 23) 39 21.5 57 37.3
p .004 .001
Preop. run-off
2 or 3 leg arteries (n¼ 60) 72 9.8 79 8.7
1 or 0 leg artery (n¼ 42) 68 17.2 76 16.6
p .94 .98
Gp. 1: group 1, CLI: Chronic limb ischemia; ALI: Acute limb ischemia;
TASC: Trans Atlantic Society Consensus.
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sel, and no severe calcification. In our experience, we
tried to optimise these ideal and infrequent conditions
by performing in 39 limbs (39%) a surgical reconstruc-
tion of the femoral bifurcation in order to deploy the
Viabahn endograft in a restored area, and in 16 limbs
a balloon angioplasty of the popliteal artery to im-
prove the outflow. However, our data shows that se-
vere TASC D lesions are still associated with
significantly lower patency rates, when compared
with simpler lesions.
Dealing with extensive SFA lesions leads us to treat
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%
Fig. 3. Actuarial primary patency (Kaplan-Meier curves) accord
A SFA lesions (n¼ 9), Red line: TASC B SFA lesions (n¼ 42), Pin
lesions, (n¼ 23), (TASC: Trans Atlantic Society Consensus 2007;poor runoff (one or none leg arteries in 42 limbs,
41%). No deaths or major amputations occurred in pa-
tients with intermittent claudication that we treated.
Some 3 patients died from myocardial infarction in
groups II (CLI) and III (ALI), giving an early mortality
of 3 and 10% respectively. These values have to be
compared, in the literature, with the death rate after
conventional surgical treatment of CLI which is be-
tween 4.7 & 13.5%13,14 and of ALI which is between
9.4 & 15%.15,16 Facing a population getting older,
with more and more associate diseases and a poor
life expectancy, we think that the endovascular treat-
ment of extensive SFA lesions can also be proposed
in patients presenting with tissue loss or, in some
cases, with acute limb ischemia. Our data sustained
this idea with 75.5% of the non-claudicant limbs in
the present study with a patent graft at 3 years.
Furthermore, all but 4 achieved limb salvage (91.8%)
at the end of follow-up.
During follow-up, among 27 Viabahn occlusion,
25 (93%) occurred during the first 10 post-operative
months, and a SFA/popliteal stenosis proximal or dis-
tal to the Viabahn endograft was always found as the
cause of occlusion when a thrombectomy was per-
formed (n¼ 8). In this study, our surveillance policy
(clinical exam and Duplex scanning at 1, 6 and
12 months, and yearly) was only able to detect these
SFA/popliteal lesions prior to Viabahn occlusion in
2 cases. This is the reason why primary assisted pa-
tency values were not calculated in this study. These
facts led us to modify the surveillance program of
these patients and to add in the future, another clini-
cal and Duplex scan at 3 and 9 months after the
procedure.19 21 23 25 27 29 31 33 35 37
onths
ing to preoperative SFA lesions ( p< 0.01). Green line: TASC
k line: TASC C SFA lesions, (n¼ 28), Black line: TASC D SFA
SFA: Superficial femoral artery).
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352 Y. S. Alimi et al.Conclusion
Use of Hemobahn/Viabahn endoprosthesis to treat
TASC B and C SFA lesions may achieve similar results
to those of bypass surgery. However, the results for
TASC D SFA lesions appear to be inferior to surgery.
Further development including larger multicenter
studies and comparison with bare stents are necessary.References
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